| Literature DB >> 34278875 |
Shitong Xia1, Sihai Wu1, Minghao Wang2.
Abstract
BACKGROUND: Accumulated evidence shows that DNA repair gene X-ray repair cross complementing group 1 (XRCC1) may determine individual susceptibility to head and neck cancer (HNC) as a major DNA repair gene. However, the results from previous studies have been conflictive and inconsistent. In order to more accurately estimate and integrate the association between XRCC1 Arg399Gln polymorphism and HNC risk, we conducted a meta-analysis including 14586 subjects.Entities:
Keywords: Arg399gln; XRCC1; head and neck cancer; polymorphism
Mesh:
Substances:
Year: 2021 PMID: 34278875 PMCID: PMC8293857 DOI: 10.1177/15330338211033060
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Figure 1.Flow diagram of the literatures selection procedure in this meta-analysis.
The Main Characteristics of the Eligible Literatures Included in the Meta-Analysis.
| No. of case | No. of control | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Year | Control source | Country | Ethnicity | Tumor site | N | AA | AG | GG | N | AA | AG | GG | HWE |
| Ammar | 2020 | Hospital | Jordan | Asian | Head & neck | 99 | 67 | 30 | 2 | 89 | 43 | 43 | 3 | 0.047 |
| Applebaum | 2009 | Healthy | USA | Mixed | Head & neck | 483 | 192 | 229 | 62 | 547 | 232 | 246 | 69 | 0.762 |
| Bogela | 2011 | Hospital | China | Asian | Larynx | 58 | 32 | 22 | 4 | 116 | 61 | 48 | 7 | 0.542 |
| Csejtei | 2009 | Healthy | Hungary | Caucasians | Head & neck | 108 | 50 | 47 | 11 | 102 | 53 | 41 | 8 | 0.985 |
| Demokan | 2005 | Healthy | Turkey | Caucasians | Oral | 95 | 42 | 41 | 12 | 98 | 39 | 46 | 13 | 0.922 |
| Dos | 2013 | Healthy | Brazil | Brazilian | Oral | 150 | 64 | 62 | 24 | 150 | 62 | 54 | 34 | 0.002 |
| Gajecka | 2005 | Healthy | Poland | Caucasians | Larynx | 293 | 106 | 153 | 34 | 319 | 124 | 145 | 50 | 0.484 |
| Gugatschka | 2011 | Healthy | Austria | Caucasians | Head & neck | 168 | 70 | 74 | 24 | 463 | 204 | 198 | 61 | 0.24 |
| Hakan | 2017 | Hospital | Turkey | Mixed | Oral | 111 | 44 | 22 | 45 | 148 | 133 | 15 | 0 | 0.516 |
| Harth | 2008 | Healthy | Germany | Caucasians | Head & neck | 310 | 114 | 166 | 30 | 300 | 143 | 121 | 36 | 0.189 |
| He | 2010 | Hospital | China | Asian | Larynx | 72 | 22 | 38 | 12 | 72 | 43 | 22 | 7 | 0.116 |
| Jelonek | 2010 | Healthy | Poland | Caucasians | Head & neck | 104 | 47 | 50 | 7 | 110 | 35 | 62 | 13 | 0.068 |
| Kietthubthew | 2006 | Hospital | Thailand | Asian | Oral | 106 | 55 | 45 | 6 | 164 | 67 | 74 | 23 | 0.724 |
| Kostrzewska-Poczekai | 2013 | Healthy | Poland | Caucasians | Head & neck | 290 | 110 | 154 | 26 | 158 | 50 | 81 | 27 | 0.55 |
| Kowalski | 2009 | Hospital | Poland | Caucasians | Head & neck | 92 | 37 | 44 | 11 | 124 | 49 | 53 | 13 | 0.253 |
| Krupa | 2011 | Hospital | Poland | Caucasians | Larynx | 253 | 93 | 111 | 49 | 253 | 105 | 113 | 35 | 0.238 |
| Kumar | 2012 | Healthy | India | Asian | Head & neck | 278 | 128 | 124 | 26 | 278 | 98 | 144 | 36 | 0.132 |
| Li | 2007 | Hospital | USA | Caucasians | Head & neck | 830 | 335 | 374 | 121 | 854 | 360 | 285 | 109 | 0.577 |
| Majumder | 2005 | Hospital | India | Asian | Oral | 310 | 135 | 143 | 32 | 348 | 158 | 163 | 27 | 0.088 |
| Majumder | 2007 | Healthy | India | Asian | Oral | 309 | 134 | 143 | 32 | 385 | 170 | 179 | 36 | 0.255 |
| Matullo | 2006 | Healthy | Italy | Caucasians | Head & neck | 82 | 34 | 38 | 10 | 1094 | 484 | 482 | 128 | 0.632 |
| Olshan | 2002 | Hospital | USA | Caucasians | Head & neck | 98 | 45 | 50 | 3 | 161 | 62 | 82 | 17 | 0.183 |
| Pelin | 2015 | Hospital | Turkey | Caucasians | Head & neck | 55 | 21 | 27 | 7 | 69 | 22 | 35 | 12 | 0.763 |
| Ramachandran | 2006 | Healthy | India | Asian | Oral | 110 | 46 | 48 | 16 | 110 | 73 | 33 | 4 | 0.91 |
| Rim | 2014 | Hospital | Tunisia | Caucasians | Head & neck | 169 | 12 | 78 | 79 | 261 | 14 | 165 | 82 | 0.001 |
| Rydzanicz | 2005 | Healthy | Poland | Caucasians | Head & neck | 182 | 63 | 98 | 21 | 143 | 59 | 63 | 21 | 0.535 |
| Sturgis | 1999 | Hospital | USA | Mixed | Head & neck | 203 | 94 | 77 | 32 | 424 | 181 | 197 | 46 | 0.483 |
| Tae | 2004 | Hospital | Korea | Asian | Head & neck | 129 | 69 | 51 | 9 | 157 | 86 | 64 | 7 | 0.25 |
| Varzim | 2003 | Healthy | Portugal | Caucasians | Larynx | 88 | 37 | 40 | 11 | 178 | 80 | 80 | 18 | 0.759 |
| Yuan | 2012 | Healthy | China | Asian | Head & neck | 390 | 221 | 146 | 23 | 886 | 481 | 339 | 66 | 0.558 |
Stratified Analyses of the Association of the XRCC1 Arg399Gln Polymorphisms With HNC Risk.
| Comparisons | No. of studies | Test of association | Analysis model | Test of heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95%CI |
| χ2 |
| I2 (%) | |||
| XRCC1 gene Arg399Gln polymorphism in total populations | ||||||||
| Allelic (A versus G) | 30 | 0.94 | 0.82-1.07 | 0.35 | Random | 177.50 | 0.001 | 84% |
| Heterozygous (AG versus GG) | 30 | 1.01 | 0.90-1.13 | 0.91 | Fixed | 56.29 | 0.002 | 48% |
| Homozygous (AA versus GG) | 30 | 0.99 | 0.81-1.21 | 0.92 | Random | 70.09 | 0.001 | 59% |
| Dominant (AA + AG versus GG) | 30 | 1.05 | 0.85-1.29 | 0.67 | Random | 91.49 | 0.001 | 68% |
| Recessive (AA versus AG + GG) | 30 | 0.93 | 0.80-1.08 | 0.35 | Random | 124.39 | 0.001 | 78% |
| XRCC1 gene Arg399Gln polymorphism in HWE | ||||||||
| Allelic (A versus G) | 27 | 0.92 | 0.80-1.06 | 0.25 | Random | 166.54 | 0.001 | 84% |
| Heterozygous (AG versus GG) | 27 | 1.05 | 0.93-1.18 | 0.41 | Fixed | 41.34 | 0.03 | 37% |
| Homozygous (AA versus GG) | 27 | 0.97 | 0.78-1.20 | 0.76 | Random | 67.57 | 0.001 | 63% |
| Dominant (AA + AG versus GG) | 27 | 1.06 | 0.86-1.31 | 0.57 | Random | 75.83 | 0.001 | 66% |
| Recessive (AA versus AG + GG) | 27 | 0.89 | 0.76-1.05 | 0.16 | Random | 115.14 | 0.001 | 77% |
| XRCC1 gene Arg399Gln polymorphism in Asian populations | ||||||||
| Allelic (A versus G) | 9 | 0.92 | 0.73-1.16 | 0.48 | Random | 41.10 | 0.001 | 81% |
| Heterozygous (AG versus GG) | 9 | 0.98 | 0.78-1.24 | 0.88 | Fixed | 8.9 | 0.35 | 10% |
| Homozygous (AA versus GG) | 9 | 0.87 | 0.54-1.39 | 0.55 | Random | 27.82 | 0.001 | 71% |
| Dominant (AA + AG versus GG) | 9 | 0.92 | 0.64-1.32 | 0.65 | Random | 17.87 | 0.02 | 55% |
| Recessive (AA versus AG + GG) | 9 | 0.91 | 0.69-1.21 | 0.53 | Random | 35.91 | 0.001 | 78% |
| XRCC1 gene Arg399Gln polymorphism in Caucasians populations | ||||||||
| Allelic (A versus G) | 15 | 1.04 | 0.94-1.15 | 0.66 | Fixed | 24.30 | 0.04 | 42% |
| Heterozygous (AG versus GG) | 15 | 1.21 | 1.04-1.42 |
| Fixed | 15.40 | 0.35 | 9% |
| Homozygous (AA versus GG) | 15 | 1.01 | 0.86-1.18 | 0.91 | Fixed | 21.72 | 0.08 | 36% |
| Dominant (AA + AG versus GG) | 15 | 1.27 | 1.02-1.60 |
| Random | 27.92 | 0.01 | 50% |
| Recessive (AA versus AG + GG) | 15 | 0.93 | 0.84-1.03 | 0.17 | Fixed | 18.70 | 0.18 | 25% |
| XRCC1 gene Arg399Gln polymorphism in Oral tumor populations | ||||||||
| Allelic (A versus G) | 6 | 0.58 | 0.30-1.12 | 0.11 | Random | 113.46 | 0.001 | 96% |
| Heterozygous (AG versus GG) | 6 | 0.77 | 0.42-1.42 | 0.40 | Random | 14.48 | 0.01 | 65% |
| Homozygous (AA versus GG) | 6 | 0.55 | 0.21-1.46 | 0.23 | Random | 36.84 | 0.001 | 86% |
| Dominant (AA + AG versus GG) | 6 | 0.61 | 0.26-1.43 | 0.26 | Random | 30.67 | 0.001 | 84% |
| Recessive (AA versus AG + GG) | 6 | 0.70 | 0.38-1.29 | 0.25 | Random | 62.09 | 0.001 | 92% |
| XRCC1 gene Arg399Gln polymorphism in Larynx tumor populations | ||||||||
| Allelic (A versus G) | 5 | 0.83 | 0.65-1.07 | 0.15 | Random | 9.99 | 0.04 | 60% |
| Heterozygous (AG versus GG) | 5 | 1.01 | 0.74-1.36 | 0.97 | Fixed | 5.27 | 0.26 | 24% |
| Homozygous (AA versus GG) | 5 | 0.80 | 0.59-1.08 | 0.15 | Fixed | 7.20 | 0.13 | 44% |
| Dominant (AA + AG versus GG) | 5 | 0.90 | 0.68-1.19 | 0.47 | Fixed | 6.25 | 0.18 | 36% |
| Recessive (AA versus AG + GG) | 5 | 0.77 | 0.56-1.07 | 0.13 | Random | 9.59 | 0.05 | 58% |
aThe bold value means P < 0.05.
Figure 2.Forest plots of the included literatures evaluating the association between XRCC1 Arg399Gln polymorphisms with HNC risk. Arg vs Gln.
Figure 3.Forest plots of the included literatures evaluating the correlation between XRCC1 Arg399Gln variants with HNC risk. (A) AA vs GG; (B) AG vs GG; (C) AA + AG vs GG; (D) AA vs AG + GG.
Figure 4.The subgroup analyses respectively based on Caucasians populations were performed to further refine the analysis association between XRCC1 Arg399Gln polymorphisms and HNC risk. (A) AG vs GG; (B) AA + AG vs GG.
Subgroup Analyses of the Association of the XRCC1 Arg399Gln Polymorphisms in Asians With Oral Tumors.
| Comparisons | No. of studies | Test of association | Analysis model | Test of heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95%CI |
| χ2 |
| I2 (%) | |||
| XRCC1 gene Arg399Gln polymorphism in Asians with oral tumor | ||||||||
| Allelic (A versus G) | 4 | 0.87 | 0.59-1.31 | 0.51 | Random | 21.74 | 0.001 | 86% |
| Heterozygous (AG versus GG) | 4 | 0.89 | 0.52-1.52 | 0.66 | Random | 6.38 | 0.09 | 53% |
| Homozygous (AA versus GG) | 4 | 0.79 | 0.34-1.83 | 0.58 | Random | 15.54 | 0.001 | 81% |
| Dominant (AA + AG versus GG) | 4 | 0.83 | 0.41-1.68 | 0.60 | Random | 11.72 | 0.008 | 74% |
| Recessive (AA versus AG + GG) | 4 | 0.87 | 0.55-1.35 | 0.53 | Random | 15.54 | 0.001 | 81% |
Figure 5.Sensitivity analysis for pooled results in this meta-analysis.
Results of Publication Bias by Egger’s and Begg’s Test for the Arg399Gln Polymorphism With HNC Risk.
| A vs G | GA vs GG | AA vs GG | AA + GA vs GG | AA vs GA + GG | ||
|---|---|---|---|---|---|---|
| Begg’s test | z | 0.21 | 0.29 | 1.36 | 1.07 | 1.03 |
|
| 0.830 | 0.775 | 0.175 | 0.284 | 0.301 | |
| Egger’s test | t | −0.55 | 0.68 | 1.55 | −0.58 | 0.70 |
|
| 0.586 | 0.499 | 0.132 | 0.565 | 0.489 |
Figure 6.Publication bias for pooled results in this meta-analysis. (A) A vs G; (B) AA vs GG; (C) AG vs GG; (D) AA + AG vs GG; (E) AA vs AG + G.